Objective To investigate the relationship between glutathione S⁃transferase P1 ( GSTP1) and ATP⁃binding cassette sub⁃family C member 2( ABCC2) genetic polymorphisms and the sensitivity of platinum⁃based chemotherapy in advanced non⁃small cell lung cancer( NSCLC) patients of Xinjiang Uygur. Methods Genetic DNA were extracted from the venous of a total of 112 Uygur patients with advanced NSCLC who received platinum⁃based chemotherapy. Among the 112 patients, there were 32 cases of pa⁃clitaxel+cisplatin regimen, 29 cases of gemcitabine+cisplatin regimen, and 51 cases of pemetrexed+cisplatin regimen. The clinical re⁃sponse was evaluated after two cycles of chemotherapy. GSTP1 rs1695 and ABCC2 rs717620, rs2273697, rs3740066 were genotyped u⁃sing PCR⁃restriction fragment length polymorphism method, and the relationship between GSTP1, ABCC2 polymorphisms and chemo⁃therapy sensitivity was analyzed. Results The genotype frequencies of GSTP1 rs1695 and ABCC2 rs717620, rs2273697, rs3740066A were accorded with Hardy⁃Weinberg equilibrium( P>0�05) . After two cycles� chemotherapy, there were 32 cases of PR, 61 cases of SD, and 19 cases of PD,and the sensitivity was 28�6%. Age, gender, pathological type, stage, ECOG score and chemotherapy were not related to sensitivity( P>0�05) . The GSTP1 rs1695 and ABCC2 rs717620 genetic polymorphisms, but not ABCC2 rs2273697 and rs3740066 were found to be related to the sensitivity( P>0�05) . Patients with GSTP1 rs1695 AA and ABCC2 rs717620 CT+TT geno⁃types showed the sensitivity of 50�0% compared to 16�7% of GSTP1 rs1695 AA and ABCC2 rs717620 CC( P<0�05) . Conclusion The GSTP1 rs1695 and ABCC2 rs717620 polymorphisms might be potential prognostic factors of clinical response in advanced NSCLC patients of Xinjiang Uygur receiving platinum⁃based chemotherapy.%目的：探讨谷胱甘肽S转移酶P1（ GSTP1）和三磷酸腺苷结合盒转运体C2（ ABCC2）基因多态性与新疆维吾尔族晚期非小细胞肺癌（NSCLC）患者化疗疗效的关系。方法采用限制性片段长度多态性聚合酶链反应（PCR⁃RFLP）技术检测112例以含铂方案化疗的新疆维吾尔族晚期NSCLC患者外周血DNA中GSTP1 rs1695和ABCC2 rs717620、rs2273697、rs3740066基因多态性；112例患者中采用紫杉醇联合顺铂方案32例，吉西他滨联合顺铂方案29例，培美曲塞联合顺铂方案51例，化疗2周期后评价疗效，并分析各基因型与化疗敏感性的关系。结果112例维吾尔族NSCLC患者GSTP1基因rs1695和ABCC2 rs717620、rs2273697、rs3740066位点基因型频率均符合Hardy⁃Weinberg平衡（ P＞0�05）。112例获PR 32例、SD 61例、PD 19例，化疗敏感率为28�6％。年龄、性别、病理类型、分期、ECOG评分及化疗方案与化疗敏感性均无关。 GSTP1 rs1695和ABCC2 rs717620基因多态性与铂类药物化疗敏感性有关，而ABCC2 rs2273697、rs3740066基因多态性与化疗敏感性无关（ P＞0�05）。 GSTP1 rs1695与ABCC2 rs717620基因联合多态性分析显示，同时携带GSTP1 rs1695 AA和ABCC2 rs717620 CT＋TT基因型患者化疗敏感率达50�0％，与携带GSTP1 rs1695 AA和ABCC2 rs717620 CC基因型（16�7％）相比，差异有统计学意义（ P＜0�05）。结论 GSTP1 rs1695和ABCC2 rs717620多态性可用于预测新疆维吾尔族晚期NSCLC患者对含铂方案化疗的疗效。
展开▼
